# Voiceover script
# This file is imported by scene files as: from narration_script import SCRIPT

SCRIPT = {
    "scene_01_intro": """
Long COVID is a lingering nightmare for millions, and at the heart of it are tiny, deadly traps called microclots. These aren't your ordinary blood clots—they're abnormal formations that clog capillaries, fueling fatigue, brain fog, and a host of other symptoms. But here's the twist: unlike normal clots that the body can handle, these microclots are self-reinforcing, making them incredibly resistant to treatment. Let's dive into why that matters and how we can break free.
    """,
    "scene_02_components": """
To understand these microclots, we need to look at their building blocks. First, there's the fibrin matrix—a tough protein network that forms the clot's structural backbone. Then, interwoven within it are NETs, or neutrophil extracellular traps. These are DNA-based webs released by immune cells called neutrophils to snare pathogens. Together, fibrin and NETs create a stable, pathological structure that's tough to dismantle.
    """,
    "scene_03_trap_mechanism": """
Now, here's where it gets really tricky. The fibrin matrix acts like a brake, suppressing neutrophils from releasing even more NETs. But at the same time, the NETs armor the fibrin, preventing the body from dissolving it. This creates a bidirectional trap—a self-reinforcing loop where each component protects the other. Try to remove one, and you just amplify the other, making the problem worse. It's a vicious cycle that keeps the clot intact.
    """,
    "scene_04_why_worse": """
You might think the obvious fix is to dissolve the fibrin matrix first with drugs like tPA, a common fibrinolytic. But experiments show this backfires spectacularly. Breaking down fibrin releases that brake on NET production, triggering a surge in NETosis—neutrophils releasing more traps. In fact, tPA can triple NET production, and those leftover NETs make the remaining clot 2.5 times harder to break. It's counterintuitive, but dissolving fibrin first just strengthens the trap.
    """,
    "scene_05_threshold_nonresponders": """
There's a critical tipping point in this trap: when NETs make up more than 40% of the clot's structure. Above this threshold, even the body's own fibrinolytic mechanisms become self-defeating. This explains why about 20% of long COVID patients don't respond to aggressive triple anticoagulation therapy. These non-responders often have high baseline levels of NET markers like MPO, confirming the trap's role in treatment failure.
    """,
    "scene_06_actionable_therapy": """
So, what's the way out? A sequential protocol: start by degrading the NETs with DNase, an enzyme that breaks down DNA. Monitor NET markers to ensure they're below that critical threshold before introducing fibrinolytic therapy. This prevents the rebound NETosis and allows effective clot clearing. It's a targeted approach with falsifiable predictions—like better outcomes when DNase is used first—ready for clinical testing.
    """,
    "scene_07_conclusion": """
In summary, long COVID microclots are more than stubborn clots—they're dynamical traps of fibrin and NETs in a self-reinforcing dance. The key to breaking free is sequential NET-degrading therapy, timing DNase before fibrinolytics. That said, this is based on in vitro simulations, so clinical validation is essential. Remember, in these traps, timing isn't just important—it's everything.
    """,
}
